Field Medical Appoints Mark A. Turco CEO
Analysis based on 7 articles · First reported Mar 16, 2026 · Last updated Mar 16, 2026
The appointment of Mark A. Turco as CEO of Field Medical is likely to be viewed positively by the market, signaling a strengthened leadership team for the clinical-stage medical technology company. This could lead to increased investor confidence in Field Medical's ability to advance its pulsed field ablation solutions and achieve its operational goals.
Field Medical, Inc., a clinical-stage medical technology company focused on pulsed field ablation (PFA) solutions for cardiac arrhythmias, announced the appointment of Mark A. Turco, MD, as its new chief executive officer, effective immediately. Dr. Turco brings over 30 years of leadership experience from cardiovascular startups and large medical device organizations, including previous roles as CEO of JC Medical, Inc. (acquired by Edwards Lifesciences) and senior leadership positions at Medtronic and Medtronic===Covidien. His background as a cardiologist and medical device executive is expected to guide Field Medical through its next phase of growth, accelerate clinical programs, and strengthen operational capabilities. Field Medical's FieldForce Ablation System has received Breakthrough Device Designation and entry into the FDA TAP Pilot Program for ventricular tachycardia.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard